Chemical Component Summary

Name(6M)-3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide
Identifiers3-azanyl-~{N}-[3-(4-azanyl-4-methyl-piperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide
FormulaC22 H23 F3 N8 O
Molecular Weight472.466
TypeNON-POLYMER
Isomeric SMILESCC1(CCN(CC1)c2cccnc2NC(=O)c3c(ncc(n3)c4c(cccn4)C(F)(F)F)N)N
InChIInChI=1S/C22H23F3N8O/c1-21(27)6-10-33(11-7-21)15-5-3-9-29-19(15)32-20(34)17-18(26)30-12-14(31-17)16-13(22(23,24)25)4-2-8-28-16/h2-5,8-9,12H,6-7,10-11,27H2,1H3,(H2,26,30)(H,29,32,34)
InChIKeyXXJXHXJWQSCNPX-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count57
Chiral Atom Count0
Bond Count60
Aromatic Bond Count18

Drug Info: DrugBank

DrugBank IDDB16059 
NameDarovasertib
Groups investigational
DescriptionIDE-196 is under investigation in clinical trial NCT03947385 (Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions).
SynonymsDarovasertib
CAS number1874276-76-2

Related Resource References

Resource NameReference
Pharos CHEMBL3982723
PubChem 118873253
ChEMBL CHEMBL3982723